Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin

WEI-CHING CHEN1,2, HUI-PING HSU3, CHUNG-YEN LI1, YA-JU YANG1, YU-HSUAN HUNG1,2, CHIEN-YU CHO1,2, CHIH-YANG WANG1,2, TZU-YANG WENG1,2 and MING-DERG LAI1,2,4

1Department of Biochemistry and Molecular Biology, 2Institute of Basic Medical Sciences, 3Department of Surgery, and 4Center for Infectious Diseases and Signaling Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.

Received April 28, 2016; Accepted September 2, 2016

DOI: 10.3892/ijo.2016.3691

Abstract. Cancer stem cell (CSC) markers have been identified for CSC isolation and proposed as therapeutic targets in various types of cancers. CD90, one of the characterized markers in liver and gastric cancer, is shown to promote cancer formation. However, the underexpression level of CD90 in ovarian cancer cells and the evidence supporting the cellular mechanism have not been investigated. In the present study, we found that the DNA copy number of CD90 is correlated with mRNA expression in ovarian cancer tissue and the ovarian cancer patients with higher CD90 have good prognosis compared to the patients with lower CD90. Although the expression of CD90 in human ovarian cancer SKOV3 cells enhances the cell proliferation by MTT and anchorage-dependent growth assay, CD90 inhibits the anchorage-independent growth ability in vitro and tumor formation in vivo. CD90 overexpression suppresses the sphere-forming ability and ALDH activity and enhances the cell apoptosis, indicating that CD90 may reduce the cell growth by the properties of CSC and anoikis. Furthermore, CD90 reduces the expression of other CSC markers, including CD133 and CD24. The inhibition of CD133 is attenuated by the mutant CD90, which is replaced with RLE domain into RLD domain. Importantly, the CD90-regulated inhibition of CD133 expression, anchorage-independent growth and signal transduction of mTOR and AMPK are restored by the β3 integrin shRNA. Our results provide evidence that CD90 mediates the antitumor formation by interacting with β3 integrin, which provides new insight that can potentially be applied in the development of therapeutic strategies in ovarian cancer.

Introduction

Ovarian cancer is one of the common gynecologic cancers. Several studies demonstrate that accumulation of genetic alteration causes aberrant gene expression and is associated with cancer progression (1). Genetic alteration contributes to the ovarian cancer progression and is associated with the ovarian cancer incidence (2,3). The alteration of tumor suppressor gene or oncogene, such as BRCA1 and NDN, was observed in ovarian cancer cells (4,5).

CD90, also called as Thy-1, is a glycoprotein and mediates the T cell activation and neurite growth (6,7). CD90 is enriched in activated endothelial cells and is attracted to melanoma cells by the integrin and syndecan (8-10). CD90 has been defined as a marker for cancer stem cell (CSC) in gastric, lung, esophageal and liver cancer. CD90+ gastric cancer stem cells possess the highest tumor initiation ability and inhibition of ERBB2 signaling by trastuzumab reducing tumorigenicity in vivo (11). Identification of lung cancer stem cell characterized by CD90 phenotype that contributes to the higher cell proliferation and stem cell marker Sox2 and Oct4 expression was demonstrated in A549 and H446 lung cancer cell lines (12). CD90-positive tumor-initiating cell population has aggressive tumor progression in esophageal cancer (13). The CD90+ cells isolated from liver cancer cell lines and clinical tumor samples are responsible for tumor formation (14). Compared to the CD90 CXCR4+ liver cancer cells, the CD90+CXCR4+ cells have higher stemness properties of sphere-forming ability and promote cancer metastasis (15). Additionally, the expression of stem cell markers, including CD133, CD90 and EpCAM, are increased in the hepatocellular carcinoma tissues with bile duct tumor thrombi compared to the tissues without bile duct tumor thrombi (16). In our previous study, CD90 was shown to play an oncogenic role in liver cancer progression via the signal axis of CD90-integrin-AMPK-CD133 and targeting CD90 and its downstream molecules may be employed as therapeutic targets (17). Notably, CD90 was decreased in nasopharyngeal carcinoma cell lines and metastatic tumor tissues. CD90 has been demonstrated to suppress myofibroblastic differentiation and the idiopathic pulmonary fibrosis tissue harbors the highly epigenetic changes of CD90 in fibroblastic foci (18). Furthermore, the expression of CD90 is not detected...
in ovarian cancer cells with tumorigenic ability and the introduction of CD90 into the tumorigenic clone reduces the tumor formation (19,20). However, the mechanism by which CD90 inhibits ovarian cancer cell growth is still largely unclear.

A previous study demonstrated that CD90 inhibits the growth of astrocytes, which provides nutrition and structural support to nerve cells. In contrast, CD90 does not affect the growth of Schwann cells, which is the component of myelin sheath (21). These data indicate that bidirectional signal transduction attributes to the interaction between neuron and microglia. Integrin family plays important roles in functions and signals of CD90 in various cells. CD90 interacts with β3 or αvβ3 integrin, thereby regulating the signaling transduction in astrocyte and neuronal cells. The trans interaction between CD90 on neuronal cells and integrin on astrocyte contributes to cell adhesion (22). The CAD neuron-like cell co-incubated with integrin αvβ3-Fc fusion protein has reduced neurite extension and the αvβ3 integrin-derived growth inhibition is triggered by the interaction between CD90 and Src (23). The cis interaction between CD90 and αvβ5 integrin are reported to prevent the activation of TGF-β and myofibroblast differentiation (24), which in turn, is a promoter of cancer formation. Our previous study indicates that there is a cis interaction between CD90 and β3 integrin in liver cancer and the cis interaction between these two molecules is required for the CD90-induced CD133 upregulation. Although CD90 has been demonstrated to play a potential tumor suppressor role in ovarian cancer, the mechanism by which CD90 inhibits ovarian cancer cell growth is unclear. The present study aimed to determine the relationship between integrin and CD90 in ovarian cancer cells and determine whether CD90 plays a tumor suppressor role in ovarian cancer cells via β3 integrin.

Our analyses from online database reveal that CD90 is downregulated in ovarian cancer tissues and the gene copy number of CD90 is correlated with the mRNA expression. Overexpression of CD90 decreases the anchorage-independent growth in vitro and tumor formation in vivo. The expression of CD90 promotes anoikis and inhibits stemness properties. Furthermore, CD90 reduces the CD133 expression, and the reduction of CD133 and anchorage-independent growth ability are rescued by the β3 integrin shRNA.

Materials and methods

Cell culture. The SKOV3 cells and stable transfectants expressing wild-type or mutant CD90 were maintained in Dulbecco's minimum essential medium (DMEM; HyClone Laboratories, Logan, UT, USA) consisting of 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO2.

Oncomine database analysis. The mRNA expression of CD90 in ovarian cancer was identified from Oncomine database as the criteria of P-value <1E-4, fold change >3, and gene ranking in the top 10% (https://www.oncomine.org/resource/login.html) (25,26). The CD90 mRNA expression was identified from Yoshihara ovarian dataset.

Kaplan-Meier plotter database analysis. The correlation between CD90 expression and post-progression survival in ovarian cancer was analyzed by Kaplan-Meier plotter database (http://kmplot.com/analysis/) (27). The hazard ratio with 95% confidence intervals and log-rank P-value was also computed.

cBioPortal database analysis. The correlation between DNA copy number and mRNA expression of CD90 in ovarian cancer is identified by cBioPortal database (http://www.cbioportal.org/) (28,29).

Establishment of CD90 transfectants. SKOV3 cells were transfected with CD90 expression vector using TurboFect (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instruction and the resistant transfected cells were selected with G418 at the concentration of 1 mg/ml. The expression of CD90 in SKOV3 stable transfectants was determined by RT-PCR and flow cytometry.

Flow cytometry. The trypsinized transfectants were incubated with anti-CD90-PE antibody (eBioscience, Inc., San Diego, CA, USA) on ice for 20 min and were resuspended in phosphate-buffered saline containing 1% BSA and 200 nM EDTA. The cells were analyzed using a FACSCalibur (BD Biosciences, San Jose, CA, USA).

MTT assay. The cell proliferation of the transfectants was analyzed by MTT assay. The cells were seeded into the 24-well plates at the density of 2x104/well. The MTT reagent was incubated for 4 h and the cell viability was determined at the absorption wavelength of 590 nm.

Colony formation assay. Colony formation was performed by seeding cells at concentrations of 5x103/well in 6-well plates. The colonies were stained with 2% methylene blue and counted after incubation for 10 days.

Soft agar assay. The anchorage-independent growth ability of the transfectants was analyzed by soft agar colony assay. Five thousand cells were prepared in 1 ml of 0.3% agar in DMEM supplemented with 10% FBS and layered onto 1.5 ml 0.6% agar in DMEM containing 10% FBS. The colonies were incubated for 3 weeks and stained with 0.2% crystal violet.

Tumorigenicity in NOD/SCID mice. The NOD/SCID mice were obtained from the Animal Center of the National Cheng Kung University (Tainan, Taiwan) and the experiments were approved by the Institutional Animal Care and Use Committee of NCKU. The stable transfectants were injected subcutaneously into NOD/SCID mice at the density of 1x107.

Anoikis assay. Anoikis was analyzed by plating the cells at the density of 5x103 into the polyHEMA-coated dish for 24 h. The cells were harvested and the apoptosis was confirmed by Annexin V and PI staining according to the manufacturer's instruction.

Western blot analysis. Antibodies against CD133 (Abcam, Cambridge, UK), CD44 (Abcam), EpCAM (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mTOR (Epitomics, Burlingame, CA, USA), CD24 (Epitomics), CD13 (Epitomics), PARP (Cell Signaling Technology, Beverly, MA, USA),
phosphor-AMPK (Cell Signaling Technology), AMPK (Cell Signaling Technology) and β-actin (Chemicon, Inc., Pittsburgh, PA, USA) were used in western blotting. Cell extracts were harvested in RIPA lysis buffer and the protein concentration was determined with Micro BCA™ protein assay kit (Millipore, Billerica, MA, USA). Protein extracts (35 µg) were fractionated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Amersham Biosciences, Piscataway, NJ, USA) using a transfer apparatus according to the manufacturer’s instructions (Hoefer Pharmacia Biotech, San Francisco, CA, USA). After incubation with 5% non-fat milk, the membranes were incubated with specific primary antibody and horseradish peroxidase-conjugated secondary antibody. The membranes were then probed with ECL western blotting detection system (Millipore) and visualized with the BioSpectrum AC imaging system.

*Sphere formation assay.* The 5x103 transfectants were plated in the ultra-low attachment plates (Corning Incorporated, Corning, NY, USA) in DMEM consisting 50 ng/ml HGF, 50 ng/ml EGF, 1% bovine serum albumin and 1% FBS. The cells were incubated for 14 days and then were counted under light microscope.

**ALDH assay.** ALDH activity was performed with the Aldelfluor® kit (StemCell Technologies, Durham, NC, USA) according to the manufacturer’s instructions. The cells were suspended in the Aldelfluor assay buffer containing ALDH substrate, with or without the ALDH inhibitor (diethylamino benzaldehyde, DEAB), and were followed by incubation at 37°C for 30 min. The ALDH activity was detected with the FACScalibur.

**Quantitative real-time reverse transcription-PCR.** Total RNA was extracted with TRIzol (MDBio, Taipei, Taiwan) and the cDNA was synthesized using M-MLV transcriptase (Promega, Madison, MI, USA) according to the manufacturer's instructions. The real-time PCR was performed using KAPA™ Probe Fast qPCR kit (Kapa Biosystems, Wilmington, MA, USA) on an Applied Biosystems StepOnePlus™ Real-Time PCR system. The CD133 primers were 5'-aagcagatagatcagaattga-3' (sense) and 5'-ccacagcagacatgaataa-3' (antisense); the CD24 primers were 5'-atggccagccagcagctttga-3' (sense) and 5'-tgccaaatatcgtcttgaggt-3' (antisense); the EpCAM primers were 5'-agttggtgcacaaaatctgtcat-3' (sense) and 5'-ctcccaagttactggttgct-3' (antisense); the HPRT primers were 5'-agttggtgcacaaaatctgtcat-3' (sense) and 5'-ctcccaagttactggttgct-3' (antisense); the CD133 primers were 5'-aagcagatagatcagaattga-3' (sense) and 5'-ccacagcagacatgaataa-3' (antisense); the CD24 primers were 5'-atggccagccagcagctttga-3' (sense) and 5'-tgccaaatatcgtcttgaggt-3' (antisense); the EpCAM primers were 5'-agttggtgcacaaaatctgtcat-3' (sense) and 5'-ctcccaagttactggttgct-3' (antisense); the HPRT primers were 5'-agttggtgcacaaaatctgtcat-3' (sense) and 5'-ctcccaagttactggttgct-3' (antisense). The reactions were incubated at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing and extension at 60°C for 1 min.

**β3 integrin-specific inhibition by shRNA.** The shRNA was obtained from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan). The β3 integrin shRNA targeting sequences is GATGCAGTGAATTGACTCAT. The production of lentiviral particles containing β3 integrin shRNA was conducted according to the protocol provided from the National RNAi Core Facility.

**Tissue array staining.** Formalin-fixed, paraffin-embedded ovarian tumor tissue array was purchased from Super BioChips (Seoul, Korea). The tissue array was deparaffinized with xylene and rehydrated in grade ethanol, and the antigen retrieval was performed by autoclaving in target retrieval buffer (Dako, Carpinteria, CA, USA). Immunohistochemical staining was performed using a monoclonal rabbit anti-CD90 antibody (clone EPR3133; Abcam) and a monoclonal mouse anti-integrin β3 antibody (Clone SAP; Millipore). The color was developed with 3-amino-9-ethylcarbazole (Dako). The sections were subsequently counterstained with the Mayer’s hematoxylin. The lesions were assessed by a medical doctor (H.P.H.).

**Statistical analysis.** The statistical analyses were performed using GraphPad Prism version 4 (GraphPad Software, Inc., La Jolla, CA, USA). The analysis was performed using unpaired t-test, one-way ANOVA analysis and two-way ANOVA analysis, respectively and the data are reported as mean ± standard deviation.

**Results**

**CD90 is underexpressed in ovarian cancer tissues.** In order to elucidate the CD90 expression in physiological situation, the CD90 expression in ovarian tumor tissues was analyzed using Oncomine database. Oncomine database analysis of ovarian cancer tissue vs. normal tissue showed that CD90 was significantly decreased in tumor tissues (Fig. 1A). The prognostic value of CD90 in ovarian cancer was analyzed using Kaplan-Meier plotter and revealed that low level of CD90 was correlated with poor survival rate (Fig. 1B). The gene copy number is important for several biological processes in normal cells and the alterations of gene copy number are associated with cancer initiation (30). We therefore studied whether the variations of gene copy number are involved in altered mRNA expression levels in ovarian cancer. The analysis from cBioPortal database showed that the increase of DNA copy number from deletion, diploid, to amplification causes the increase in mRNA expression, indicating that DNA copy number is correlated with the mRNA expression (Fig. 1C).

**CD90 inhibits tumorigenicity in SKOV3 cells.** To study whether the CD90 affected ovarian cancer cell growth, SKOV3 cells were transfected with a plasmid encoding CD90. Ectopic expression of CD90 mRNA was analyzed by RT-PCR analysis, and the surface expression of CD90 was detected by flow cytometry (Fig. 2A and B). Ectopic expression of CD90 promoted the cell proliferation by MTT analysis, respectively and the data are reported as mean ± standard deviation.

**CD90 promotes anoikis and reduces sphere-forming ability.** Since the effect of CD90 on anchorage-dependent growth in *in vitro* was not correlated with the tumor growth *in vivo*, we investigated whether CD90 affected anoikis, which is closely related with the anchorage-independent growth. Expression of exogenous CD90 promoted cell apoptosis when SKOV3 cells were cultured on poly-HEMA-coated
CHEN et al.: CD90 INHIBIT OVARIAN CANCER GROWTH

1884

dish (Fig. 3A). CD90 transfectants displayed higher level of cleaved poly(ADP-ribose) polymerase (cleaved PARP), which indicates caspase-dependent activation (Fig. 3B). In addition, expression of CD90 decreased the sphere formation in ultra-low attachment culture dishes and aldehyde dehydrogenase activity, which characterize the subpopulation of cells with CSC properties (Fig. 4A and B). These data indicate that the inhibition of tumor growth is correlated with the alteration of characteristics of CSC.

CD90 decreases the expression of stem cell markers CD133 and CD24. Since CSC markers were used to identify CSCs, we then investigated whether ectopic expression of CD90
influences the expression of other CSC markers. The expression of CD133 and CD24 was decreased in the SKOV3 CD90 transfectant (Fig. 4C). There was no statistically significant difference in CD44, EpCAM and CD13 expression between SKOV3 CD90 transfectant and the parental cell line SKOV3 (Fig. 4C). The inhibition of CD133 expression was further confirmed by western blotting (Fig. 4D). Our previous study reported that CD90 promoted CD133 expression through the elevated mTOR phosphorylation and decreased AMPK phosphorylation in liver cancer (17). Next we studied whether the mTOR and AMPK were involved in the inhibition of CD133 by ectopic expression of CD90 in ovarian cancer. SKOV3 CD90 transfectants had lower levels of mTOR phosphorylation and higher levels of AMPK phosphorylation (Fig. 4E).

The CD90 RLD domain affects anchorage-independent growth and CD133 expression. Given that CD90 has been shown to promote liver cancer progression through interaction with β3 integrin with its RLD sequence, we sought to determine whether the RLD domain of CD90 mediated the signal transduction in regulating CD133 expression in ovarian cancer. The RLD residue of CD90 was replaced with RLE, and the mutant CD90 was delivered into SKOV3 cells. The mutant CD90 did not inhibit anchorage-independent growth (Fig. 5A). The inhibition of CD133 mRNA by CD90 was rescued by the mutant CD90 (Fig. 5B). Besides, the alteration of AMPK and mTOR phosphorylation was attenuated in SKOV3 transfectant expressing mutant CD90 (Fig. 5C).

Silencing of β3 integrin increases anchorage-independent growth and CD133 expression. Given the effect of the RLD domain of CD90 in mediating CD133 inhibition, we next determined whether CD90 regulated its effects through β3 integrin in SKOV3 cells. The β3 integrin shRNA was delivered to SKOV3 CD90 transfectants and the knockdown efficacy was determined by quantitative RT-PCR (Fig. 6A). The anchorage-independent growth ability and CD133 mRNA expression was increased by β3 integrin shRNA (Fig. 6B and C). CD90-induced phosphorylation of mTOR and AMPK were attenuated after silencing β3 integrin expression (Fig. 6D). In addition, β3 integrin shRNA did not alter the CD90 expression in either SKOV3 stable CD90 transfectants or SKOV3 cells transiently transfectected with CD90 by flow cytometric analysis (Fig. 6E). To further verify the physiological role of CD90 and β3 integrin on tumor cells, we exploited the tissue array to analyze the CD90 and β3 integrin expression by immunohis...
tochemistry and found that both expression of CD90 and β3 integrin were observed in tumor tissues (Fig. 6F), indicating the physiological interaction between CD90 and β3 integrin on tumor cells.

Discussion

In the present study, we demonstrated that CD90 is decreased in ovarian cancer tissue and the lower expression level of CD90 predicts poor prognosis. CD90 functions as a tumor suppressor gene in ovarian cancer and growth inhibition is associated with the characteristic of anoikis and stemness properties, including sphere-forming ability and ALDH activity. We found decreased expression of CD133 in the CD90 transfectants compared to the parental SKOV3 cells. Signaling analyses reveal that AMPK and mTOR are correlated with the inhibition of CD133. Furthermore, the mutant CD90 attenuates the signaling transduction of AMPK/mTOR, CD133 expression and the anchorage-independent growth ability. The inhibition of CD133 expression and anchorage-independent growth by CD90 is restored by β3 integrin shRNA.

In the present study, we examined the effect of β3 integrin shRNA on anchorage-independent growth, CD133 expression and mTOR/AMPK signal molecules in the transfectant expressing ectopic CD90 (Fig. 6B-D), and found that β3 integrin shRNA attenuated CD90-induced phenomena, indicating that β3 integrin is associated with CD90-mediated phenotype alteration. Previous study showed that β3 integrin downregulates SKOV3 cell growth (31), indicating that β3 integrin may restore the anchorage-independent growth in ovarian cancer cells in a CD90-independent manner. Nevertheless, mutation of the β3 integrin binding domain in CD90 significantly attenuated its ability on CD133 expression and anchorage-independent growth (Fig. 5). Furthermore, β3 integrin shRNA did not alter CD90 expression in either SKOV3 stable CD90 transfectants or SKOV3 cells transiently transfected with CD90 (Fig. 6E). Altogether, the inhibitory effect of CD90 on CD133 expression and anchorage-independent growth may be regulated directly through the activation of β3 integrin.

In this study, we clarified the role of CD90 in SKOV3 cell line, which is an adenocarcinoma ovarian cancer cell. Serous adenocarcinoma is the common type of ovarian cancer and the
Table I. CD90 expression in ovarian cancer from Oncomine database.

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Cancer subtype</th>
<th>Fold change</th>
<th>P-value</th>
<th>Gene rank (Top %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoshihara</td>
<td>Peritoneum vs. ovarian serous adenocarcinoma</td>
<td>-7.662</td>
<td>2.06E-08</td>
<td>7</td>
</tr>
<tr>
<td>Hendrix</td>
<td>Ovary vs. ovarian serous adenocarcinoma</td>
<td>1.265</td>
<td>0.015</td>
<td>29</td>
</tr>
<tr>
<td>Adib</td>
<td>Ovary vs. ovarian serous adenocarcinoma</td>
<td>1.539</td>
<td>0.014</td>
<td>10</td>
</tr>
<tr>
<td>Bonome</td>
<td>Ovarian surface epithelium vs. ovarian carcinoma</td>
<td>2.608</td>
<td>4.78E-09</td>
<td>7</td>
</tr>
<tr>
<td>Welsh</td>
<td>Ovary vs. ovarian serous surface papillary carcinoma</td>
<td>2.026</td>
<td>0.016</td>
<td>32</td>
</tr>
<tr>
<td>TCGA</td>
<td>Ovary vs. ovarian serous cystadenocarcinoma</td>
<td>2.615</td>
<td>0.005</td>
<td>31</td>
</tr>
<tr>
<td>Lu</td>
<td>Ovarian surface epithelium vs. ovarian clear cell adenocarcinoma</td>
<td>1.546</td>
<td>0.033</td>
<td>18</td>
</tr>
</tbody>
</table>

High-grade serous adenocarcinoma arises from elsewhere in the peritoneal cavity. In addition, we identified CD90 expression from microarray datasets in Oncomine database as the criteria of P-value <1E-4, fold change >3, and gene ranking in the top 10% in Gene Summary View and only one dataset from Yoshihara was identified. Therefore, we identified the CD90 expression from this dataset comparing the normal peritoneum and ovarian serous adenocarcinoma in Fig. 1A. We further checked the other six datasets under the criteria of P<0.05 and found that CD90 was increased in different types of cancer tissues, including carcinoma, papillary carcinoma, cystadenocarcinoma, clear cell adenocarcinoma and serous adenocarcinoma (Table I), indicating that CD90 expression has tissue-specific expression pattern. It is interesting to note that the expression of CD90 in serous adenocarcinoma was decreased in Yoshihara's dataset, but increased in Adib's and Hendrix's datasets. The clinical cancer tissues from Adib's dataset were identified from College Hospitals NHS Trust located in UK. The samples from Hendrix's dataset were derived from the University of Michigan Health System and the John Hopkins Hospital located in USA. By contrast, Yoshihara obtained the clinical tissues from the Department of Obstetrics and Gynecology of Niigata University located in Japan. A previous study showed that Asian ovarian cancer patient has good disease-specific survival compared to Caucasian ovarian cancer patient, and the disease-specific survival of Asian immigrants was higher than U.S born Asians (32), indicating the important effect of genetic and environmental factors on tumor development.

Oncomine database indicated that CD90 expression is increased in liver cancer, but decreased in ovarian cancer tissue as the criteria of P-value <1E-4, fold change >3, and gene ranking in the top 10% in Gene Summary View. The differential CD90 expression between liver and ovarian cancer tissues is in accordance with the finding that oncogenic role of CD90 in liver cancer in our previous study and the tumor suppressor role of CD90 in ovarian cancer in the present study. In addition, the results of this study describing the effects of CD90 on CD133 expression and mTOR and AMPK phosphorylation in ovarian cancer are opposite to the results of our previous study in liver cancer (17). These data indicate that CD90 play different roles in different cancers.

Integrin functions as heterodimer and is generated from at least 18 α and 8 β subunits to form 24 distinct receptors. The distinct integrin heterodimer binds to different extracellular matrix components to regulate diverse biological responses (33). Integrin mediates the signal transduction during carcinogenesis and it has multiple functions to regulate cancer progression within different tumors. The expression of αvβ3 and αvβ5 integrin is highly expressed in breast cancer and is associated with the increased tumor size and bone metastasis (34,35). In contrast, the α2β1 integrin is decreased in the breast cancer tissue and the restoration of α2β1 integrin inhibits the tumorigenic ability (36). The overexpression of β3 integrin decreases the tumor weight and metastasis in ovarian cancer cells (31), and the expression of β3 integrin is associated with the good prognosis in ovarian cancer (37). Integrin has been demonstrated to correlate with the cancer stem cell growth and the α6 integrin is co-expressed with conventional CSC markers in glioblastoma stem cells (38,39). The α1 and β5 integrin promote CD133+ prostate cancer stem cell (PCSC) differentiation (40). These studies suggest that CD90 may play a tumor suppressor role in ovarian cancer at least in part mediated via β3 integrin.

Tumor suppressor gene is functional for growth inhibition. It is interesting to note that CD90 inhibited the tumorigenic ability in vitro and in vivo, but increased the cell proliferation in SKOV3 cells. We further found that CD90 decreased the stemness properties of ALDH activity and sphere formation ability, indicating that CD90 is critical for the characteristics of stem cells. Previous studies show that the balance between proliferation and quiescence regulation is important for stem cells, and mesenchymal stem cell decreases the proliferation for the long-term self-renewal preservation (41,42). Horsley et al (43) found that NFATc1 contributes to the balance between quiescence and proliferation of skin stem cells and regulates the quiescence stage by repressing CDK4 expression. In addition, the cancer stem-like cells are thought to have the slow-cycling phenotype (44). Consequently, we propose that CD90-mediated proliferation may occur through the alteration of CSC property. Previous studies have demonstrated that mTOR signal pathway is involved in cancer stem cell growth and targeting mTOR by inhibitor can be used as cancer therapy (45,46). AMPK, which is a downstream signal molecule of mTOR, has been demonstrated to regulate drug resistance and cancer stem cell growth (47). In our previous study, CD90 promoted CD133 expression through the signal axis of mTOR and AMPK, thereby inducing liver tumor formation (17). Therefore, we suggest that CD90 triggered the same signal axis, but activated the opposite phosphorylation of mTOR and AMPK for liver and ovarian cancer development.
In conclusion, CD90 is underexpressed in ovarian cancer and CD90 overexpression decreases tumor growth via β3 integrin. The β3 integrin suppression by shRNA is able to restore the CD90-regulated tumor inhibition. The present study provides new insight into the contribution of CD90 in ovarian cancer, implying the application of therapy in the future.

Acknowledgements

This study was supported by the grant to M.D. Lai, no. 101-2320-B-006-028-MY3 from the Ministry of Science and Technology, Taiwan.

References


